Compare XMAX & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMAX | CGC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.8M | 467.3M |
| IPO Year | 2009 | 2023 |
| Metric | XMAX | CGC |
|---|---|---|
| Price | $8.98 | $1.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 574.0K | ★ 3.7M |
| Earning Date | N/A | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.51 | 84.17 |
| EPS | ★ 0.62 | N/A |
| Revenue | $12,744,871.00 | ★ $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | $13.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.10 | $0.84 |
| 52 Week High | $9.40 | $2.38 |
| Indicator | XMAX | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 65.75 |
| Support Level | $8.33 | $1.01 |
| Resistance Level | $9.34 | $1.08 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 51.41 | 90.91 |
XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.